NWBS Northw.Bio Regs

 

TIDMNWBS TIDMNWBT 
 
RNS Number : 0804R 
Northwest Biotherapeutics Inc 
23 April 2009 
 

Northwest Biotherapeutics, Inc. 
(the "Company") 
 
 
New Issue of Shares and Total Voting Rights 
 
 
Bethesda, MD  Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO) 
announces today that further to the Company's announcement of 7 April 2009, 
1,577,019 new ordinary shares of 0.001 each (Reg S) are expected to be admitted 
to trading on AIM on 24 April 2009. The Company's issued share capital will 
therefore comprise 40,360,878 Reg S common stock of 0.001 each in the Company 
(AIM: NWBS) and 4,709,094 unrestricted common stock of 0.001 each in the Company 
(AIM: NWBT). 
 
 
About Northwest Biotherapeutics 
 
 
Northwest Biotherapeutics is a biotechnology company focused on developing 
immunotherapy products that treat cancers more effectively than current 
treatments, without toxicity, on a cost-effective basis. The Company has two 
broad platform technologies: dendritic cell-based vaccines, and therapeutic 
antibodies. The Company is currently conducting a large clinical trial in 
Glioblastoma multiforme, which is designed and powered to serve as a pivotal 
trial. The Company has also received clearance from the FDA for a large Phase 
III trial in prostate cancer, and clearance from the FDA for Phase I trials in 
five other cancers. The Company also has a second technology platform, involving 
monoclonal antibodies to CXCR4, which is at the late pre-clinical development 
stage. 
 
 
For further information, please visit the company web site at www.nwbio.com. 
 
 
Disclaimer 
 
 
Statements made in this news release that are not historical facts are 
forward-looking statements within the meaning of the Private Securities 
Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," 
and similar expressions are intended to identify forward-looking statements. 
Actual results may differ materially from those projected in any forward-looking 
statement. Specifically, there are a number of important factors that could 
cause actual results to differ materially from those anticipated. Additional 
information on these and other factors, which could affect the company's 
results, is included in its Securities and Exchange Commission ("SEC") filings. 
Finally, there may be other factors not mentioned above or included in the 
company's SEC filings that may cause actual results to differ materially those 
projected in any forward-looking statement. You should not place undue reliance 
on any forward-looking statements. The company assumes no obligation to update 
any forward-looking statements as a result of new information, future events or 
developments, except as required by securities laws. 
 
 
For further information, please contact: 
 
 
+----------------------------------------------------------------+----------------------+ 
| Northwest Biotherapeutics, Inc.                                |                      | 
+----------------------------------------------------------------+----------------------+ 
| Alton L. Boynton, Chief Executive Officer                      | +1 240 497 9024      | 
+----------------------------------------------------------------+----------------------+ 
|                                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
| Buchanan Communications                                        |                      | 
+----------------------------------------------------------------+----------------------+ 
| Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane Johnson /    | +44 (0)20 7466 5000  | 
| Catherine Breen                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
|                                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
| Collins Stewart Europe Limited                                 |                      | 
+----------------------------------------------------------------+----------------------+ 
| Adrian Hadden/ Adam Cowen                                      | +44 (0)20 7523 8350  | 
+----------------------------------------------------------------+----------------------+ 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 IOEEXLFLKZBEBBD 
 

Northw.Bio Regs (LSE:NWBS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Northw.Bio Regs (LSE:NWBS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024